Laura Staunton

Dr. Laura Staunton


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2024 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Open access
PDF file
LSLaura Staunton
Laura Staunton
JBJarlath C. Bolger
Jarlath C. Bolger
RARakesh Ahmed
Rakesh Ahmed
WBWaqas T. Butt
Waqas T. Butt
JRJohn V. Reynolds
John V. Reynolds
CDClaire L Donohoe
Claire L Donohoe
Background: Patient and procedure factors are considered in the decision-making process for surgical repair of hiatal hernias. Recurrence is multi-factorial and has been shown to be related to size, type, BMI and age. Aims: This study examined recurrence rates in a single institution, identified areas for improved surgical technique, and re-assessed recurrence following implantation of a quality improvement initiative. Methods: A retrospective review of patients undergoing hiatal hernia repair surgery between 2018 and 2022 was conducted. Demographics, pre-operative characteristics, intra-operative procedures and recurrence rates were reviewed. Results: Seventy-five patients from 2018 to 2020 and 34 patients from 2021 to 2022 were identified. The recurrence rate was 21% in 2018–2020, with 14% requiring a revisional procedure. Recurrence and re-operation were subsequently reduced to 6% in 2021 and 2022, which was statistically significant (p = 0.043). There was an increase in gastropexy from 21% to 41% following the review (p = 0.032), which was mainly reserved for large and giant hernias. Procedural and literature review, alongside gastropexy, can be attributed to recurrence rate reduction. Conclusions: It is important to educate patients on the likelihood and risk factors of recurrence. A comprehensive review of procedures and a quality improvement program in our facility for hiatal hernia repair is shown to reduce recurrence.

8 March 2022 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
LSLaura Staunton
Laura Staunton
LCLaura Casey
Laura Casey
VYVincent K. Young
Vincent K. Young
GFGerard J. Fitzmaurice
Gerard J. Fitzmaurice
Laura Mary Staunton, M.B., B.Ch., B.A.O., Laura Casey, M.B., M.R.C.S.I., Vincent K. Young, M.D., F.R.C.S.I. (CTh), Gerard J. Fitzmaurice, M.Sc., F.R.C.S.I. (CTh). J Chest Surg 2022;55:174-6. https://doi.org/10.5090/jcs.21.115

14 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
LSLaura Staunton
Laura Staunton
AAAli Alisinan
Ali Alisinan
TKTaya Keating
Taya Keating
RWRebecca Weedle
Rebecca Weedle
LTLara Toerien
Lara Toerien
GFGerard J. Fitzmaurice
Gerard J. Fitzmaurice
Background and ObjectivesPulmonary carcinoid tumours are rare, representing 1-2% of all lung cancers. Surgical resection offers curative-intent treatment with 5-year survival rates of 50-70% for atypical carcinoid (AC) and 90% for typical carcinoid (TC) tumours. We review management and outcomes, including survival statistics and prognostic factors for recurrence over a 14-year period at our institution, the largest volume thoracic surgical oncology centre in Ireland.MethodsPatients who underwent surgical resection between January 1st 2010 and April 30th 2024 for pulmonary carcinoid tumours were identified. STATABE version 18.0 performed Fischer’s exact test and student’s t-test. Kaplan Meier graphs were used for survival analysis and Cox regression to assess prognostic factors.Results191 patients underwent surgical resection. 21% were upstaged from clinical N0. N2 disease (p=0.181, 95% CI: 0.55 – 24.42) and adjuvant chemotherapy (p=0.180, 95%, CI 0.54-26.48) were not statistically significant for overall survival. Mean time to recurrence was 37.5 (SD+-5.66) months; 2% of TC and 23% of AC recurred. No patient with Stage I disease recurred; 58% of recurrence was in Stage III atypical carcinoid tumours. Overall survival at 5-years was 96.3% (TC 98.7%, AC 87.7%) and 10-years was 93.8% (TC 98.7%, AC 73.7%).ConclusionOccult nodal disease occurred in 48% of atypical carcinoid tumours and adjuvant chemotherapy did not appear to yield a survival advantage. 58% of recurrences occurred in Stage III atypical carcinoid tumours. Early diagnosis remains paramount as surgical resection of pulmonary carcinoid tumours yields an excellent overall survival at 5-years of 96.3% and 10-years of 93.8%.

23 June 2025 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Open access
PDF file
LSLaura Staunton
Laura Staunton
SESarah Early
Sarah Early
MTMichael Tolan
Michael Tolan
VYVincent K. Young
Vincent K. Young
SJSaleem M. Jahangeer
Saleem M. Jahangeer
Background: Guidelines recommend early aspirin loading (150–325 mg) within 6 h of coronary artery bypass grafting (CABG), which improves patency of vein grafts. Due to bleeding concerns, this is not standard practice. Aims: The aim of this study is to review early aspirin administration, within 6 h of CABG, to determine if there is an increased risk of bleeding. Methods: Bleeding risk was evaluated in 160 patients, undergoing CABG procedure from January 2022 to February 2023. Patients were divided into two groups: those that received 300 mg of aspirin within 6 h (group 1) and those that did not (group 2). Drainage output from different timepoints, red cell, platelet transfusion rates, pericardial effusion, and re-exploration for bleeding were reviewed. Statistical analysis was performed using STATA/BE version 18.0. Significance was demonstrated when p value < 0.05. Results: Mean output drainage at 24 h was 695.7 mL for group 1 and 712.7 mL for group 2. Considering 11 timepoints, there were no significant difference between groups (p values = 0.731–0.117). Transfusion rates for red cells (p = 0.734) and platelets (p = 0.274), re-exploration for bleeding (p = 0.694), and pericardial effusion rates (p = 0.472) also showed no statistical difference. Conclusions: A comprehensive review of drainage output, red cell, platelet transfusion, re-exploration for bleeding, and pericardial effusion rates was performed, post early aspirin administration. Aspirin (300 mg) given within 6 h of CABG surgery did not lead to increased bleeding and associated complications.